Home
Resources
Publications
Interleukin 12 in Combination With Anti-Interleukin 10 Reverses Graft Prolongation After Portal Venous Immunization

Interleukin 12 in Combination With Anti-Interleukin 10 Reverses Graft Prolongation After Portal Venous Immunization

R M Gorczynski, N Hozumi, S Wolf, Z Chen

Transplantation. 1995 Dec 15;60(11):1337-41.

PMID: 8525531

Abstract:

Portal venous pretransplantation transfusion augments allogeneic skin graft survival in mice transplanted across multiple minor histocompatibility barriers. We have shown in earlier studies that this is correlated with preferential activation for production of type-2 cytokines (interleukin [IL]-4 and IL-10) and decreased production of type-1 cytokines (IL-2 and interferon-gamma). We show that recombinant IL-12, in association with anti-IL-10 monoclonal antibody, can reverse in vivo the graft prolongation afforded by portal venous immunization and the altered cytokine production that follows. These alterations are in turn associated with increased expression of messenger RNA for interferon-gamma, IL-2, and IL-12 and decreased expression of IL-4, IL-10, and IL-13, as determined by non-quantitative polymerase chain reaction using cells obtained from lymph nodes draining the graft. Recombinant IL-12 in vitro also produces dose-related inhibition of activation for production of type-2 cytokines.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
IAR42413338	Monoclonal Anti-Interleukin-10 antibody produced in mouse			Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: